Literature DB >> 16689754

Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction.

P-Y Liu1, Y-H Li, H-L Wu, T-H Chao, L-M Tsai, L-J Lin, G-Y Shi, J-H Chen.   

Abstract

BACKGROUND: Oxidation of low density lipoproteins is an initial step of atherogenesis that generates pro-inflammatory phospholipids, including platelet-activating factor (PAF). PAF is degraded by PAF-acetylhydrolase (PAF-AH), which has been postulated to be a risk factor for myocardial infarction (MI). The role of PAF-AH for the onset of premature MI is unclear.
METHODS: Polymorphisms located in putatively functional regions were investigated in a cohort of patients having premature MI onset prior to 46 years of age (n = 200) and a sex-age-matched control group (n = 200). The activity of PAF-AH and coronary angiograms were evaluated for the severity of coronary atherosclerosis.
RESULTS: The V allele of A379V (exon 11) polymorphism on PAF-AH gene was more frequent in patients with premature MI (P = 0.001). This V allele polymorphism was also associated with a lower activity of plasma PAF-AH and a more complex coronary atherosclerosis (p Trends <0.05). Multiple logistic regression analysis showed that this polymorphism was an independent risk factor (Odds Ratio [OR] 1.66, 95% CI 1.14.1 to 5.80, P = 0.008) as well as smoking (OR 3.72, 95% CI 1.77 to 9.28, P = 0.001), diabetes mellitus (OR 2.25, 95% CI 1.40 to 5.32, P = 0.007) and hypertension (OR 1.88, 95% CI 1.25 to 5.36, P = 0.003) for the onset of premature MI.
CONCLUSION: We conclude that a functional and significant association between the A379V polymorphism on exon 11 of PAF-AH gene and premature MI exists in this Taiwanese population. This polymorphism is significantly associated with the PAF-AH activity and the severity of coronary atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16689754     DOI: 10.1111/j.1538-7836.2006.01895.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  20 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Effects of A379V variant of the Lp-PLA 2 gene on Lp-PLA 2 activity and markers of oxidative stress and endothelial function in Koreans.

Authors:  Jey Sook Chae; Jung Hyun Kwak; Minjoo Kim; Kyoung Hun Shin; Sang-Hyun Lee; Tae-Sook Jeong; Jong Ho Lee
Journal:  J Thromb Thrombolysis       Date:  2014-11       Impact factor: 2.300

Review 3.  Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.

Authors:  Giuseppe Maiolino; Valeria Bisogni; Giacomo Rossitto; Gian Paolo Rossi
Journal:  World J Cardiol       Date:  2015-10-26

Review 4.  The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis.

Authors:  Ralph A H Stewart; Harvey D White
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

5.  Interaction between nonsynonymous polymorphisms in PLA2G7 gene and smoking on the risk of coronary heart disease in a Chinese population.

Authors:  Yunpeng Chi; Conghong Shi; Xiaojiang Zhang; Yang Xi
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

Review 6.  Lipoprotein-associated phospholipase A2: The story continues.

Authors:  Fubao Huang; Kai Wang; Jianhua Shen
Journal:  Med Res Rev       Date:  2019-05-29       Impact factor: 12.944

7.  Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets.

Authors:  Beth S Sutton; David R Crosslin; Svati H Shah; Sarah C Nelson; Anthony Bassil; A Brent Hale; Carol Haynes; Pascal J Goldschmidt-Clermont; Jeffery M Vance; David Seo; William E Kraus; Simon G Gregory; Elizabeth R Hauser
Journal:  Hum Mol Genet       Date:  2008-01-18       Impact factor: 6.150

8.  Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study.

Authors:  Sunil Suchindran; David Rivedal; John R Guyton; Tom Milledge; Xiaoyi Gao; Ashlee Benjamin; Jennifer Rowell; Geoffrey S Ginsburg; Jeanette J McCarthy
Journal:  PLoS Genet       Date:  2010-04-29       Impact factor: 5.917

9.  Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study.

Authors:  Renate Schnabel; Josée Dupuis; Martin G Larson; Kathryn L Lunetta; Sander J Robins; Yanyan Zhu; Jian Rong; Xiaoyan Yin; Heide A Stirnadel; Jeanne J Nelson; Peter W F Wilson; John F Keaney; Ramachandran S Vasan; Emelia J Benjamin
Journal:  Atherosclerosis       Date:  2008-11-05       Impact factor: 5.162

10.  Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study.

Authors:  Liping Hou; Shufeng Chen; Hongjiang Yu; Xiangfeng Lu; Jianhong Chen; Laiyuan Wang; Jianfeng Huang; Zhongjie Fan; Dongfeng Gu
Journal:  Hum Genet       Date:  2008-11-26       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.